一项针对类风湿性关节炎患者的血小板活化因子拮抗剂的双盲、安慰剂对照研究。
A double blind, placebo controlled study of a platelet activating factor antagonist in patients with rheumatoid arthritis.
作者信息
Hilliquin P, Chermat-Izard V, Menkes C J
机构信息
Institut de Rhumatologie, Hôpital Cochin, Paris, France.
出版信息
J Rheumatol. 1998 Aug;25(8):1502-7.
OBJECTIVE
To evaluate the efficacy and tolerance of a platelet activating factor-acether (PAF) antagonist, BN 50730, in patients with rheumatoid arthritis (RA).
METHODS
A total of 56 patients with active RA were enrolled in a multicenter, double blind, placebo controlled study of BN 50730. Patients received either BN 50730 (40 mg orally bid) or placebo for 84 days.
RESULTS
Treatment with BN 50730 resulted in no improvement and was no more effective than placebo in improving clinical and biological indices of RA activity. Adverse events were observed in the 2 treatment groups, and BN 50730 was generally well tolerated.
CONCLUSION
PAF antagonist BN 50730 at a daily dose of 80 mg was ineffective in the treatment of RA.
目的
评估血小板活化因子-乙酰醚（PAF）拮抗剂BN 50730对类风湿关节炎（RA）患者的疗效及耐受性。
方法
共56例活动期RA患者纳入一项关于BN 50730的多中心、双盲、安慰剂对照研究。患者接受BN 50730（口服40 mg，每日两次）或安慰剂治疗84天。
结果
BN 50730治疗未带来改善，在改善RA活动的临床和生物学指标方面并不比安慰剂更有效。两个治疗组均观察到不良事件，且BN 50730总体耐受性良好。
结论
每日剂量80 mg的PAF拮抗剂BN 50730治疗RA无效。
Zotero 插件